Consistent with these results, pathway activity analysis based on RPPA data showed that LASS2-high tumors had lower activity of EMT-related and Wnt pathways than LASS2-low tumors in multiple cancers, including bladder cancer, breast cancer, lung cancer, stomach cancer, and testicular cancer (Additional file 2: Fig. S3H, Additional file 8). This evidence concerns the gene CERS2 and breast carcinoma.